AACR	American Association for Cancer Research
ADCC	antibody-dependent cellular cytotoxicity
ADC	antibody-drug conjugate
APC	antigen-presenting cell
ASCO	American Society of Clinical Oncology
ASTCT	American Society for Transplantation and Cellular Therapy
ATS	American Thoracic Society
BsAb	bispecific antibody
CAR	chimeric antigen receptor
CD3	cluster of differentiation 3
CD137	4-1BB, tumor necrosis factor receptor superfamily member 9
CDR	complementarity-determining region
CI	confidence interval
CEACAM5	carcinoembryonic antigen-related cell adhesion molecule5
CLDN6	claudin-6
CLDN18.2	claudin-18.2
CNS	central nervous system
CRS	cytokine release syndrome
DLL3	delta-like ligand3
DOR	duration of response
EMT	epithelial-to-mesenchymal transition
ES-SCLC	extensive-stage small cell lung cancer
FDA	U.S. Food and Drug Administration
FOLR1	folate receptor alpha
GPC3	glypican-3
HER2	human epidermal growth factor receptor 2 (ErbB2)
HR	hazard ratio
IHC	immunohistochemistry
ICI	immune checkpoint inhibitor
ICANS	immune effector cell-associated neurotoxicity syndrome
IgG	immunoglobulin G
IV	intravenous
LCNEC	large cell neuroendocrine carcinoma
LAG-3	lymphocyte-activation gene 3
MDSC	myeloid-derived suppressor cell
MHC-I	major histocompatibility complex class I
MUC1	mucin1
NCI	National Cancer Institute
NCCN	National Comprehensive Cancer Network
NEC	neuroendocrine carcinoma
NICD	Notch intracellular domain
NK	natural killer (cell)
NSCLC	non-small cell lung cancer
ORR	objective response rate
OS	overall survival
PD-1	programmed cell death protein1
PD-L1	programmed death-ligand1
PFS	progression-free survival
PSMA	prostate-specific membrane antigen
SCLC	small cell lung cancer
TAA	tumor-associated antigen
TCE	T-cell engager
TCR	T-cell receptor
TIM-3	T-cell immunoglobulin and mucin domain-3
TIL	tumor-infiltrating lymphocyte
TME	tumor microenvironment
TROP-2	trophoblast cell-surface antigen2
Treg	regulatory T cell
VISTA	V-domain Ig suppressor of T-cell activation
BiTE	bispecific T-cell engager
DART	Dual-Affinity Re-Targeting antibody
ImmTAC	Immune-mobilizing monoclonal T-cell receptor Against Cancer
TriTAC	trispecific T-cell-activating construct
STEAP1	Six-Transmembrane Epithelial Antigen of the Prostate 1
CTC	circulating tumor cell
TKI	tyrosine kinase inhibitor
EGFR	epidermal growth factor receptor
ALK	anaplastic lymphoma kinase
ROS1	ROS proto-oncogene 1
KRAS	Kirsten rat sarcoma viral proto-oncogene
ASCL1	achaete-scute homolog 1
YAP1	Yes-associated protein 1
TIGIT	T cell immunoreceptor with Ig and ITIM domains
AMPK	AMP-activated protein kinase
mTOR	mechanistic target of rapamycin
TGF-β	transforming growth factor beta
IL-6	interleukin-6
IL-10	interleukin-10
CARTOX-10	CAR T-cell therapy-associated toxicity grading tool
ICE	immune effector cell encephalopathy assessment tool
LCNEC-L	large cell neuroendocrine carcinoma of the lung
epNEC	extrapulmonary neuroendocrine carcinoma
2L+	second-line or later
RECIST	Response Evaluation Criteria in Solid Tumors
RMST	restricted mean survival time